Avitar to acquire Genua:
This article was originally published in Clinica
Avitar is expanding its presence in the rapid diagnostic test market with the planned stock purchase of Genua, a privately-held diagnostics company. Genua developed its Rapid Saliva Kits for HIV and hepatitis which include a custom-designed form of Avitar's Accu-sorb saliva collection devices. Genua recently revealed positive results of correlation studies for these tests, conducted at the Nassau County Medical Center, East Meadow, New York. Furthermore, Genua owns distribution rights to drugs-of-abuse and pregnancy tests. Avitar is a manufacturer of a range of healthcare products including Hydrasorbd, a line of polyurethane dressings.
You may also be interested in...
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.